Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors
12 Juni 2023 - 3:49PM
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”,
“Company”, “We” or “Us”), today announced that effective today,
Henry A. McKinnell, Jr, Ph.D., former Chairman and Chief Executive
Officer of Pfizer Inc., has been appointed to the Company’s Board
of Directors. Dr. McKinnell brings significant leadership to
Nexcella: developing, launching and commercializing drug
candidates; building world-class operations; and forming
international alliances.
After joining Pfizer, Inc. in 1971, Dr. McKinnell held positions
of increasing responsibility around the world including Chairman
and Chief Executive Officer from 2001 until his retirement in
2006. In addition to his experience at Pfizer, Dr. McKinnell
has served as an independent director of ChemoCentryx, acquired by
Amgen for $3.7 billion in 2022; former Chairman/CEO of Optimer
Pharmaceuticals, acquired by Cubist Pharmaceuticals (now Merck
& Co.) for $535 million in 2013; independent director of
ExxonMobil from 2002 to 2007; and independent director of Agiliti
from 2017-2019. Most recently, Dr. McKinnell was the independent
Chairman of Moody’s Corporation from 2012 to 2021.
“We are honored to have Dr. McKinnell join the Nexcella Board of
Directors. He has an unparalleled track record as a pharmaceutical
executive and strategic leader, with extensive experience building
pre-eminent, world-class organizations,” said Ilya Rachman, M.D.,
Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel
Morris, Chief Financial Officer of ImmixBio, added, “Dr.
McKinnell’s experience will be invaluable as we progress NXC-201
through clinical development in AL amyloidosis and multiple
myeloma. Dr. McKinnell’s leadership and skills in our industry, as
well as his contributions to other areas of human welfare, are
internationally recognized. We look forward to benefiting from his
valuable insights.”
Dr. McKinnell commented, “My interest and commitment to the
translation of scientific discoveries to the bedside so patients
can benefit makes joining the Nexcella Board an honor and hopefully
the beginning of a journey which will benefit seriously ill
patients around the world.”
Dr. McKinnell is the Chairman Emeritus of the Pharmaceutical
Research and Manufacturers of America (PhRMA). He also served as a
Senior Advisor to Toyota Motor Corporation's International Advisory
Board and the Thomas H. Lee Private Equity Partnership. Dr.
McKinnell holds a bachelor’s degree in business from the University
of British Columbia and an M.B.A. and Ph.D. from Stanford
University Graduate School of Business.
About Nexcella, Inc.
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc
(Nasdaq:IMMX), is a Los Angeles, CA based clinical-stage
biopharmaceutical company engaged in the discovery and development
of novel cell therapies for oncology and other indications. Our
lead candidate, next generation BCMA-targeted CAR-T NXC-201 for
multiple myeloma and AL amyloidosis has produced 92% and 100%
response rates in each indication, respectively, as of February 9,
2023 across 58 patients. We believe NXC-201 has potential to be the
world’s first outpatient CAR-T. Our N-GENIUS platform allows us to
discover, develop, and manufacture cutting-edge cell therapies for
patients in need. To learn more about Nexcella, Inc. visit us at
www.nexcella.com.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a
clinical-stage biopharmaceutical company pioneering a novel class
of Tissue-Specific Therapeutics (TSTx) targeting oncology and
immuno-dysregulated diseases. Our lead asset is IMX-110, currently
in Phase 1b/2a clinical trials as a monotherapy and in its
IMMINENT-01 combination clinical trial with BeiGene’s anti-PD-1,
tisleilizumab, for which patient dosing begin in Feb 2023. IMX-110
holds orphan drug designation (ODD) by the FDA for soft tissue
sarcoma, and has received Rare Pediatric Disease Designation (RPDD)
by the FDA the treatment of rhabdomyosarcoma, a life-threatening
form of cancer in children. RPDD qualifies ImmixBio to receive fast
track review and a priority review voucher (PRV) at the time of
marketing approval of IMX-110. Additionally, ImmixBio subsidiary
Nexcella, Inc, developing CAR-T NXC-201 for multiple myeloma and AL
amyloidosis, with 92% and 100% response rates in each indication,
respectively, as of February 9, 2023. Learn more at
www.immixbio.com.
Forward Looking Statements
This press release contains “forward-looking statements”
Forward-looking statements reflect our current view about future
events. When used in this press release, the words “anticipate,”
“believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the
negative of these terms and similar expressions, as they relate to
us or our management, identify forward-looking statements. Such
statements, include, but are not limited to, statements contained
in this press release relating to our business strategy, our future
operating results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned including: the uncertainties related
to market conditions and other factors described more fully in the
section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report
on Form 10-K for the year ended December 31, 2022, and other
periodic reports filed with the Securities and Exchange Commission.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Immix Biopharma, Inc.
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Factors or events that could cause our actual results to differ
may emerge from time to time, and it is not possible for us to
predict all of them. We cannot guarantee future results, levels of
activity, performance or achievements.
ContactsStern Investor RelationsSuzanne
MessereManaging DirectorSuzanne.Messere@sternir.com
Company Contactirteam@immixbio.com
Immix Biopharma (NASDAQ:IMMX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Immix Biopharma (NASDAQ:IMMX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024